Question 1.Managerial Epidemiology: What

17 Jun Question 1.Managerial Epidemiology: What

Question
1.Managerial Epidemiology: What is the cost-effectiveness analysis and what is it used for in healthcare and public health? Provide an example study. (Points : 10)

Question 2.2.Qualitative, Quantitative (Cause-Effect): You are the Chief Operating Officer of a hospital. The Human Resources Director reports to you. Two of your valued Directors have a random drug screening for controlled substances with a group of hospital cohorts, and the result comes up as positive for heroine. Your experience with epidemiology and your understanding of cause-effect makes you skeptical of these general screening results. You request that the specimens be sent out to a specialty lab for confirmatory testing with gas chromatography specific for heroine. The results of the confirmatory testing show that both Directors are negative (0 mg/dl) for all control substances, including heroine. A further investigation revealed that both Directors attended a morning meeting the day of the random test and had eaten poppy seed muffins. You do research and find that poppy seed muffins produce a byproduct in the body that mimics opiates/heroine in a screening.

Discuss why these results occurred , i.e., the two very different results between a screening, and the confirmatory test in terms of a) qualitative and b) quantitative testing, c) specificity, d) reliability.

(Points : 10)

Question 3.3.Research Methods: Why is the randomized clinical trial (RCT) research considered the “gold standard” in clinical epidemiology research? What is an IRB and why is it requirement when performing research with human beings? (Points : 10)

Question 4.4.Decision Making: Clinical epidemiology research should be based on empirical evident. Define empirical evidence and what it means in decision making in both private and public health decision making in regard to interventions, i.e., the implementation of medical testing, processes or public health programs. (Points : 10)

Question 5.5.Risk Factor Research: Why is the Framingham Heart Study a pivotal research program in healthcare today? What are some of the milestones the study has given to clinical epidemiology? (Points : 10)

Question 6.6.Case 1 of 2 (50 Pts): Cost-Effectiveness Analysis (CEA): In Wu et al. (2006) researchers performed an analysis to evaluate the cost-effectiveness of doing stool DNA testing in addition to other types of traditional screenings, i.e., fecal occult blood testing annually, flexible sigmoidoscopy or colonoscopy, every 5 and 10 years for colorectal cancer in countries where colon cancer prevalence is low. Also, evaluated was the cost/benefit of doing no screenings (Wu, 2006).

The subjects were people 50 to 75 years of age in Taiwan. The researchers used the annual cost of $13,000 per life-year saved (which is roughly the per capita GNP of) as the ceiling ratio for assessing whether DNA testing was cost-effective (Wu, 2006).

Simulated results for screening strategies to prevent Colon Rectal Cancer (CRC)

Variable

Screening Strategy

No Screening

DNA (3yrs)

DNA (5yrs)

DNA (10yrs)

Occult Blood

Flexible Sigmoid. (5yrs)

Colonoscopy (10 yrs)

a. Total cases of CRC, n

2,917

2,435

2,654

2,710

2,129

2,253

1,780

b. CRC deaths, n

1,729

1,345

1,467

1,574

1,059

1,328

1,077

c. Perforation deaths, n

0

3

2

1

5

3

12

e. Reduction in CRC incidence, %

0

17

9

7

27

23

39

f. Reduction in CRC mortality, %

0

22

15

9

39

23

39

g. Life expectancy, year

15.7337

15.7476

15.7434

15.74

15.7584

15.7477

15.759

h. Total costs, thousand $

22,022

35,637

31,077

26,856

19,824

24,909

21,843

i. Incremental life-year saved, year

0

1,390

970

626

2,464

1,383

2,530

j. Incremental cost, thousand $

0

13,615

9,054

4,834

-2,198

2,887

-180

k. Incremental cost ($)/life-years saved compared with no screening

0

9,794

9,335

7,717

Dominant ‡

2,087

Dominant †

* Values obtain from a cohort of 100,000 persons 50 years of age who were followed for 25 years.

† The other screening strategy is more effective and less costly than stool DNA testing strategy.

‡ The screening is more effective and less costly than No Screening.

Adapted from: Wu et al. BMC Cancer 2006 6:136 doi:10.1186/1471-2407-6-136

_____________
Reference:
Wu, Grace HM. Wang, Yi-Ming . Yen, Amy MF. Wong, Jau-Min Lai, Hsin-Chih Warwick, Jane and Chen, Tony HH. (2006) Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer 2006, 6:136 doi:10.1186/1471-2407-6-136

QUESTIONS: In your own words and
1) From the research results shown in the chart above, which type of screening had the highest and which had the lowest reduction in colon-rectal cancer mortality?

2) How do you interpret the findings (Conclusion) in regard to the A-K results in regard to the cost/effectives of doing DNA-testing at 3 years, 5 years, 10 years, or not doing DNA tests at all?

(Points : 50)

Question 7.7.NOTE: Essay Question is in 2 parts. This is Part 1 to be completed and then go <next>, to Part 2 and complete it.

Case #2 of 2: (50 pts) Cost/Benefit literature review for vaginal birth after cesarean (VBAC)

A client had a cesarean delivery in a hospital setting for breech presentation with her first pregnancy. She is pregnant again and after exploring her delivery options, has decided she wants to attempt a vaginal birth after cesarean (VBAC). She has had an uncomplicated pregnancy this time and the fetus is not breech. The same OB-GYN will be assisting in her delivery. The OB-GYN performs a systematic review of the literature to assess the benefits and harms of VBAC versus repeat cesarean delivery.

Part 1 of 2: Researching Empirical Evidence

1. What kinds and sources of data does the OB-GYN need to review in order to make a rational clinical planning decision?

2. Which types of studies available on this topic would be the most useful in clinical decision making?

3. What types of studies would you want to exclude?

4. Why would there be a lack of randomized clinical trials (RCT’s) available to address this clinical question?

(Points : 20)